触媒制药 CPRX 深 沪
已收盘 11-14 16:00:00 美东时间
23.18
+0.160
+0.70%
华盛通- 最 高23.44
- 今 开22.83
- 成交量 115.20万股
- 最 低 22.80
- 昨 收 23.02
- 总市值 28.28亿
- 52周最高 26.58
- 市盈率 静 17.67
- 换手率 0.94%
- 52周最低 19.05
- 委 比 -1.37%
- 总股本 1.22亿
- 历史最高 26.58
- 量 比 0.75
- 振 幅 2.78%
- 历史最低 0.37
- 每 手 1
- 风险率 1.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Citigroup Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $33
Citigroup analyst Samantha Semenkow maintains Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and raises the price target from $31 to $33.
11-08 04:53
Catalyst Pharmaceuticals Raises FY2025 Sales Guidance from $545.000M-$565.000M to $565.000M-$585.000M vs $562.053M Est
Catalyst Pharmaceuticals (NASDAQ:CPRX) raises FY2025 sales outlook from $545.000 million-$565.000 million to $565.000 million-$585.000 million vs $562.053 million estimate.
11-06 05:18
Catalyst Pharmaceuticals Q3 Adj. EPS $0.68 Beats $0.33 Estimate, Sales $148.392M Beat $136.802M Estimate
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.33 by 104.82 percent. This is a 19.3 percent increase over earnings of $0.57 per share
11-06 05:18
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), a biopharmaceutical company focused on rare and difficult-to-treat diseases, announced that CEO Rich Daly and other executives will participate in the Jefferies Global Healthcare Conference in London on November 17, 2025, at 2:00 pm GMT. The webcast will be available under the Investors section on the Company's website, www.catalystpharma.com, with a replay available for at least 30 days. Catalyst is...
11-03 13:03
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
Catalyst Pharmaceuticals announced that data developed by the company will be presented at upcoming scientific conferences, including the Child Neurology Society (CNS) Annual Meeting and the American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. The presentations focus on glucocorticoid use in Duchenne muscular dystrophy, patient characteristics in Lambert Eaton myasthenic syndrome, and other rare disease resea...
10-09 12:03
Catalyst Pharmaceuticals announces $200M share repurchase program through 2026
Catalyst Pharmaceuticals (NASDAQ:CPRX) has authorized a new share repurchase program of up to $200M. The program allows for the repurchase of outstanding common stock between October 1, 2025, and Dece...
10-01 20:31
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program
Pharmaceutical company Catalyst Pharmaceuticals announced a $200 million share repurchase program through December 31, 2026, funded by its strong cash reserves of over $650 million as of June 2025. CEO Richard Daly highlighted the company's solid financial health and commitment to delivering value to shareholders while maintaining its strategic growth focus in rare disease treatments. Repurchases may occur via open market or private transactions,...
10-01 12:03
